According to Arvinas's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 28.1674. At the end of 2023 the company had a P/S ratio of 28.9.
Year | P/S ratio | Change |
---|---|---|
2023 | 28.9 | 120.4% |
2022 | 13.1 | -85.94% |
2021 | 93.1 | -49.46% |
2020 | 184 | 394.46% |
2019 | 37.3 | 28.4% |
2018 | 29.0 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | N/A | N/A | ๐บ๐ธ USA |